c-Met Regulatory Composition for Hepatic Cell Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for liver diseases, such as hepatitis, often fail to address early damage effectively due to lack of noticeable symptoms and irreversible hepatocyte death, making it difficult to recover liver function even with existing drugs.
Innovation Solution
A c-Met regulatory composition comprising DMB (4,7-Dimethoxy-5-methyl-1,3-benzodioxole) and Antrodin A, which promotes hepatic cell regeneration by regulating gene expression related to hepatocyte cytothesis and regeneration, reducing oxidative stress, and maintaining normal hepatic cell activity without cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are administered to treat liver disease, then some therapeutic effect may be achieved, but they cannot effectively repair damaged hepatic cells or promote hepatocyte regeneration when hepatocytes have died
Solution Approach 1:
The patent changes the chemical parameters by introducing specific compounds (DMB and Antrodin A) with defined concentration ranges (DMB: 1.25-20 ppm, Antrodin A: 8.75-140 ppm) to activate c-Met signaling pathway and promote hepatocyte regeneration, moving beyond conventional drug parameters
Solution Approach 2:
The patent combines two active compounds (DMB and Antrodin A) in a composite formulation with specific concentration ratios (1:2 to 1:10, preferably 1:5 to 1:10), creating a synergistic effect that enhances both hepatoprotection and regeneration capabilities
2Productivity
If compounds are used to promote hepatic cell growth, then cell regeneration may be enhanced, but cytotoxicity may occur
Solution Approach 1:
The patent establishes specific concentration parameters (DMB: 1.25-20 ppm, Antrodin A: 8.75-140 ppm) that optimize regeneration promotion while maintaining safety margins below cytotoxic thresholds, as determined through dose-response studies
Solution Approach 2:
The patent uses c-Met signaling pathway as a biological intermediary mechanism through which the compounds exert their regenerative effects indirectly, activating endogenous repair pathways rather than directly forcing cell division, thereby reducing cytotoxic risk
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively repairs damaged hepatic cells, promotes regeneration, and improves liver function, as demonstrated by increased cell viability and gene expression levels, with a safe and non-toxic profile for treating liver diseases.
Implementation Method 1
regulating gene expression related to hepatocyte cytothesis and regeneration, such as c-Met, Notch, etc.
Implementation Method 2
reducing intracellular free radicals or oxidative stress
Data Source
AI summary
The invention discloses a c-Met regulatory composition and its method for treating liver disease, a main component of the c-Met regulatory composition comprises Antrodin A and/or DMB (4,7-Dimethoxy-5-methyl-1,3-benzodioxole) capable of effectively regulating gene expression related to cell regeneration and cytothesis in hepatic cells, such as c-Met, Notch, etc., to achieve efficacies of repairing damaged hepatic cells and promoting hepatocyte regeneration.